Fact CheckerSign in

NCT07876791Not yet recruiting

Multimodality Assessment of Myocardial Reperfusion After Primary Percutaneous Coronary Intervention

Multimodality Assessment of Myocardial Reperfusion After Primary Percutaneous Coronary Intervention: Integration of Artificial Intelligence-Derived Electrocardiogram Features, Angiographic Parameters, and Cardiac Magnetic Resonance.

Source: ClinicalTrials.gov · Last updated 15 Oct 2026

Brief summary (registry, in English)

This study aims to evaluate myocardial reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Although primary PCI successfully restores blood flow in the blocked coronary artery, some patients continue to have impaired blood flow within the small vessels of the heart muscle, a condition known as microvascular obstruction (MVO). This complication may be associated with greater myocardial injury and poorer clinical outcomes. The study will investigate whether artificial intelligence (AI)-derived electrocardiographic (ECG) features, coronary angiographic parameters, and cardiac magnetic resonance (CMR) findings can provide complementary information about myocardial reperfusion. Patients undergoing primary PCI will be assessed using ECG and angiographic findings, while CMR will be used to evaluate myocardial injury and microvascular obstruction. The main objective is to determine whether combining AI-derived ECG features and angiographic parameters can improve the prediction of CMR-detected microvascular obstruction after primary PCI. The findings may help identify patients at increased risk of impaired myocardial reperfusion and support future risk assessment strategies following STEMI.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
90 (estimated)
First submitted
9 Oct 2026
Start date
1 Oct 2026
Primary completion date
1 Oct 2028
Lead sponsor
Assiut University
NCT number
NCT07876791

What you commit to

  • Study type: Observational
  • Planned participants: 90
  • From 1 Oct 2026 to the primary completion date, 1 Oct 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • Age ≥18 years.
  • First acute STEMI diagnosed according to contemporary guideline criteria and selected for a primary PCI strategy.
  • Identifiable infarct-related coronary artery treated by primary PCI.
  • Successful restoration of epicardial coronary flow, preferably final TIMI grade 3 flow for the primary mechanistic cohort.
  • Technically adequate 12-lead ECG before reperfusion and standardized post-reperfusion ECG.
  • Angiograms of adequate quality for TIMI flow, MBG and cTFC assessment.
  • Ability to undergo contrast-enhanced CMR during the index admission.
  • Written informed consent for study participation and follow-up. Exclusion criteria
  • Previous myocardial infarction with established scar likely to confound CMR infarct characterization or ECG interpretation.
  • Previous CABG.
  • Known cardiomyopathy or pre-existing significant LV systolic dysfunction unrelated to the index STEMI.
  • Significant primary valvular heart disease.
  • Ventricular paced rhythm or other ECG condition that prevents reliable prespecified ECG analysis, according to the requirements of the AI platform.
  • Persistent severe hemodynamic instability or other clinical condition preventing safe CMR.
  • Contraindication to MRI or gadolinium contrast according to institutional CMR policy.
  • Non-diagnostic CMR for the primary endpoint.
  • Poor-quality angiography precluding core reperfusion measurements.
  • Refusal or inability to provide informed consent.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.